GDC-0623

In vitro Kinase assays

0.14 μM of purified inactive recombinant MEK-1 protein is preincubated with inhibitors in 15 μL of kinase buffer including (20 mM MOPS pH7.2, 25 mM beta glycerol phosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 1 mM DTT, 100 μM ATP, 15 mM MgCl2). After incubating 10 minutes at 30°C, 1 ng of BRAF, CRAF or BRAF V600E combined with 0.5 μg of inactive recombinant ERK2 is added to the reaction in total volume of 20 μL. After incubating 30 minutes at 30°C the reaction is stopped by adding Laemmle sample buffer. Enzyme activity is measured by determining level of phosphor-MEK by SDS-PAGE. Immunoreactive proteins are visualized with SuperSignal West Pico Chemiluminescent Substrate.

Cell lines

KRAS mutant HCT116 or SW620 cells

Preparation method

Soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0.01-0.15 μmol/L; 3h-48 h;

Applications

GDC-0623 dose- and time-dependently up-regulated the pro-apoptotic BH3-only protein BIM in HCT116 cells or KRAS mutant HCT116 or SW620 cells. GDC-0623 inhibited cellular proliferation with EC50 values of 4 nM, 53 nM, 11 nM, 18 nM and 94 nM for A375 (BRAFV600E), HCT116 (KRASG13D), COLO 205, HT-29, and HCT116 cells, respectively.

Animal models

Mice bearing A375, MiaPaCa-2, and HCT116 xenografts

Dosage form

40 mg/kg, oral gavage (PO), by mouth once a day, for 20 days

Applications

GDC-0623 showed tumour growth inhibition of 120% and 115% in MiaPaCa-2 and HCT116 xenografts tumour models, respectively.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K., Price, S., Heald, R., Hewitt, J. F., Zak, M., Peck, A., Orr, C., Merchant, M., Hoeflich, K. P., Chan, J., Luoh, S. M., Anderson, D. J., Ludlam, M. J., Wiesmann, C., Ultsch, M., Friedman, L. S., Malek, S. and Belvin, M. (2013) Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 501, 232-236

2. Zaanan, A., Okamoto, K., Kawakami, H., Khazaie, K., Huang, S. and Sinicrope, F. A. (2015) The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. J Biol Chem. 290, 23838-23849